INTERPHEX: Please tell us
how your career started.
Marian L. McKee, PhD
nally went to college with
grand ideas of a career
in medicine. I quickly dis-
covered I loved working in
the lab way too much, so
I decided that my grand
ideas would be taking
place there for the rest of my career. And
so it has proven to be. More than 25 years
later, I’m still as passionate about this as
I was when I did my first two years as a
lab technician at Duke University Medical
INTERPHEX: What is the biggest challenge
you have faced in the industry?
The biggest challenge of my career
has actually been a constant throughout my
career. That challenge is an ever-changing
industry with continuously evolving re-
quirements. Knowing how to manage the
interface between existing and traditional
culture-based methods, as well as the more
forward thinking molecular and alternative
methods, is a truly intriguing challenge.
INTERPHEX: Where do you see the industry
going in the next 10 years? Your area of
I definitely need to understand
what’s happening in the future, but don't
consider a 10-year timeline. I’m too focused
on the immediate future. That being said,
in 10 years, I still see myself in the industry,
still leading teams in the lab, pushing the in-
dustry to the limits. I would still like to be at
the intersect between traditional and novel
approaches, adopting new technologies
that continue to drive advancement in the
pharma and biopharma industry. ■
Marian L. McKee,
INTERPHEX: What are you known for
professionally? What is your area of
Paul Priebe (Sartorius Stedim Biotech):
an expert in single-use technology implemen-
tation into biopharmaceutical processes and
the development and management of support
teams to facilitate our end customers in im-
INTERPHEX: What is the biggest challenge you
have faced in the industry?
Despite having been in use for more than 20 years, sin-
gle-use technology remains an immature technology for our in-
dustry. Only within the past few years has this been recognized
and major efforts are under way to get through the next phase of
maturity the industry needs, the establishment of standards.
INTERPHEX: What are you most passionate about professionally?
What most excites you about your work and the contribution(s)
I am dedicated to push single-use technology through the
maturation that needs to take place. Whether that is by helping
shape Sartorius-Stedim's product and service portfolio, customer
support staff, or developing consensus standards together with
end users and competitors, everything I do is intended to contrib-
ute toward bringing single-use technologies to the next level.
INTERPHEX: How do you feel the industry changed or evolved in
In single-use, the realization of the needs to take the next
step in maturity of this technology has been a somewhat recent
development and it is one that urgently needs to be addressed.
INTERPHEX: Has there been any significant advancement within
your area of expertise?
Single-use technology now covers the entire bio-process.
The idea of complete single use processes is no longer a dream,
but a reality.
INTERPHEX: Where do you see the industry going in the next 10
years? Your area of expertise?
Single-use technology will reach a state of maturity that
gives all the advantages while eliminating some of the current is-
sues or risks. ■
in this issue
Click to subscribe to this magazine
article text for page
< previous story
next story >
Share this page with a friend
Save to “My Stuff”
Subscribe to this magazine